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Background/purpose
Rhabdomyosarcoma (RMS) is the most common soft
tissue sarcoma in children. Since patients with high-risk
RMS have limited treatment options and a poor prog-
nosis, and late complications including growth distur-
bance and secondary cancer induced by chemotherapy
or radiation therapy are essential problems, novel thera-
pies are urgently needed. C-type natriuretic peptide
(CNP) has physiological activity mainly for mesenchymal
cells to inhibit cell proliferation. We hypothesized that
CNP attenuates proliferation of human RMS, a malig-
nant mesenchymal tumor and provide rationale for
using CNP to treat RMS.
Experimental design
Gene expression of guanylyl cyclase B (GC-B), receptor
of the CNP in rhabdomyosarcoma clinical samples and
cell lines was assessed by using quantitative polymerase
chain reaction. To ascertain biological activity of CNP in
RMS cells, cyclic guanosine monophosphate (cGMP), the
second messenger molecule which is produced by the
activation of GC-B and serves as the major signaling
molecule was measured following addition of CNP. How-
ever, cGMP is quickly degraded by phosphodiesterases
and thereby biological activity becomes deactivated.
Therefore, sildenafil, a selective inhibitor of phosphodies-
terase 5 (PDE5) was added to CNP to prolong or enhance
the effects of physiological processes mediated by cGMP
by inhibiting its degradation. The in vitro and in vivo
efficacy of CNP and sildenafil was evaluated alone and in
combination.
Results
GC-B expression was seen in all alveolar and embryonal
clinical samples which had higher GC-B expression than
RMS cell lines. Since RD and RMS-YM cell lines had
considerably lower GC-B expression than the clinical
samples and KYM-1 and RH30 had no detectable
expression, GC-B stable expression cell lines, RD-GC-B
was established to mimic the clinical samples. CNP
increased the rate of cGMP accumulation in RMS cells
depending on concentration of this peptide. Combina-
tions of CNP and sildenafil synergistically inhibited cell
growth of RD-GC-B cells by inhibiting extracellular-
signal-regulated kinase (Erk), the major signal for cell pro-
liferation in RMS. The synergistic effect on growth and
reduction of phosphorylated Erk as tumor pharmacody-
namic biomarker were also confirmed in a mouse xenograft
model.
Conclusions
These results suggest that CNP in combination with silde-
nafil may have clinical efficacy for treating RMS patients.
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